

Table S1.

Treatment schedule		Oral Semaglutide	OW Semaglutide	p value
Monotherapy		1 (0,9%)	1 (0,6%)	0,75
Dual Therapy		24 (20,9%)	67 (37,9%)	0,0022
	Add-on to metformin	22 (19,15%)	65 (36,7%)	0,0016
	Add-on to basal insulin	0	2 (1,2%)	0,25
	Add-on to SGLT2-i	2 (1,75%)	0	0,07
Triple Therapy		14 (12,2%)	33 (18,6%)	0,14
	Add-on Met+Basal	2 (1,75%)	16 (9%)	0,011
	Add-on Met+SGLT2i	8 (6,95%)	4 (2,2%)	0,048
	Add-on Met+Pio	2 (1,75%)	6 (3,4%)	0,4
	Add-on Met+SUs	2 (1,75%)	3 (1,7%)	0,9
	Add-on BB	0	1 (0,6%)	0,4
	Add-on Met/Empa+Basal	0	3 (1,7%)	0,16
Replacement therapy		76 (66%)	76 (42,9%)	0,0001
	DPP4i (\pm SGLT2i o SUs)	31 (26,95%)	21 (11,8%)	0,0016
	SUs	19 (16,5%)	11 (6,2%)	0,0057
	GLP1-RA	9 (7,8%)	12 (6,7%)	0,7
	SGLT2i	8 (6,95%)	11 (6,2%)	0,8
	Metformin	0	2 (1,2%)	0,25
	Pioglitazone	4 (3,5%)	0	0,012
	Acarbose	0	1 (0,6%)	0,4
	Insulin (basal and/or rapid analogues)	5 (4,3%)	18 (10,2%)	0,07
Post-replacement therapy (*)	+Metformin	33 (43,5%)	35 (46,1%)	0,7
	+Basal Insulin	7 (9,2%)	5 (6,6%)	0,5
	+Pioglitazone	3 (3,9%)	0	0,08
	+SGLT2i	2 (2,6%)	0	0,15
	+Met+Basal	11 (14,5%)	14 (18,5%)	0,5
	+Met+SGLT2i	13 (17,1%)	1 (1,3%)	0,0008
	+Met+Pio	1 (1,3%)	7 (9,2%)	0,029
	+Met+SUs	0	3 (3,9%)	0,08
	+SGLT2i+Basal	0	3 (3,9%)	0,08
	+Met+Pio+SGLT2i	0	1 (1,3%)	0,3
	Monotherapy	6 (7,9%)	5 (6,6%)	0,7
	+Met+SGLT2i+Basal	0	1 (1,3%)	0,3
	+ BB (\pm Met)	0	1 (1,3%)	0,3

(*)Percentage calculated on the total number of patient who received od/ow semaglutide as replacement therapy